The prognostic values of the peroxiredoxins family in ovarian cancer

Abstract

Purpose: Peroxiredoxins (PRDXs) are a family of antioxidant enzymes with six identified mammalian isoforms (PRDX1-6). PRDX expression is up-regulated in various types of solid tumors; however, individual PRDX expression, and its impact on prognostic value in ovarian cancer patients, remains unclear.Methods: PRDXs family protein expression profiles in normal ovarian tissues and ovarian cancer tissues were examined using the Human Protein Atlas database. Then, the prognostic roles of PRDX family members in several sets of clinical data (histology, pathological grades, clinical stages, and applied chemotherapy) in ovarian cancer patients were investigated using the Kaplan-Meier plotter.Results: PRDXs family protein expression in ovarian cancer tissues was elevated compared with normal ovarian tissues. Meanwhile, elevated expression of PRDX3, PRDX5, and PRDX6 mRNAs showed poorer overall survival (OS); PRDX5 and PRDX6 also predicted poor progression-free survival (PFS) for ovarian cancer patients. Furthermore, PRDX3 played significant prognostic roles, particularly in poor differentiation and late-stage serous ovarian cancer patients. Additionally, PRDX5 predicted a lower PFS in all ovarian cancer patients treated with Platin, Taxol, and Taxol+Platin chemotherapy. PRDX3 and PRDX6 also showed poor PFS in patients treated with Platin chemotherapy. Furthermore, PRDX3 and PRDX5 indicated lower OS in patients treated with these three chemotherapeutic agents. PRDX6 predicted a poorer OS in patients treated with Taxol and Taxol+Platin chemotherapy.Conclusion: These results suggest that there are distinct prognostic values of PRDX family members in patients with ovarian cancer, and that the expression of PRDX3, PRDX5, and PRDX6 mRNAs are a useful prognostic indicator in the effect of chemotherapy in ovarian cancer patients.

Keywords: Kaplan-Meier plotter; PRDXs; The Human Protein Atlas; ovarian carcinoma; prognosis.

Figure 1. Comparison of the expression profile of PRDX1 in normal ovarian tissues and ovarian cancer tissues

Representative immunohistochemistry images of PRDX1 protein expression in normal ovarian tissues (A) and ovarian cancer tissues (B). Images were downloaded from the Human Protein Atlas database (http://www.proteinatlas.org/).

Figure 2. Comparison of the expression profile of PRDX2 in normal ovarian tissues and ovarian cancer tissues

Representative immunohistochemistry images of PRDX2 protein expression in normal ovarian tissues (A) and ovarian cancer tissues (B). Images were downloaded from the Human Protein Atlas database (http://www.proteinatlas.org/).

Figure 3. Comparison of the expression profile of PRDX3 in normal ovarian tissues and ovarian cancer tissues

Representative immunohistochemistry images of PRDX3 protein expression in normal ovarian tissues (A) and ovarian cancer tissues (B). Images were downloaded from the Human Protein Atlas database (http://www.proteinatlas.org/).

Figure 4. Comparison of the expression profile of PRDX4 in normal ovarian tissues and ovarian cancer tissues

Representative immunohistochemistry images of PRDX4 protein expression in normal ovarian tissues (A) and ovarian cancer tissues (B). Images were downloaded from the Human Protein Atlas database (http://www.proteinatlas.org/).

Figure 5. Comparison of the expression profile of PRDX5 in normal ovarian tissues and ovarian cancer tissues

Representative immunohistochemistry images of PRDX5 protein expression in normal ovarian tissues (A) and ovarian cancer tissues (B). Images were downloaded from the Human Protein Atlas database (http://www.proteinatlas.org/).

Figure 6. Comparison of the expression profile of PRDX6 in normal ovarian tissues and ovarian cancer tissues

Representative immunohistochemistry images of PRDX6 protein expression in normal ovarian tissues (A) and ovarian cancer tissues (B). Images were downloaded from the Human Protein Atlas database (http://www.proteinatlas.org/).

Figure 7. The prognostic value of peroxiredoxin (PRDX) family expression in overall survival (OS) of all ovarian cancer patients

(A) OS curves were plotted for PRDX1 (n=1656). (B) OS curves were plotted for PRDX2 (n=1656). (C) OS curves were plotted for PRDX3 (n=1656). (D) OS curves were plotted for PRDX4 (n=1656). (E) OS curves were plotted for PRDX5 (n=655). (F) OS curves were plotted for PRDX6 (n=1656).

Figure 8. The prognostic value of peroxiredoxin (PRDX) family expression in progression-free survival (PFS) of all ovarian cancer patients

(A) PFS curves were plotted for PRDX1 (n=1435). (B) PFS curves were plotted for PRDX2 (n=1435). (C) PFS curves were plotted for PRDX3 (n=1435). (D) PFS curves were plotted for PRDX4 (n=1435). (E) PFS curves were plotted for PRDX5 (n=614). (F) PFS curves were plotted for PRDX6 (n=1435).